New drug cocktail aims to tackle tough esophageal cancer
NCT ID NCT06339619
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of three drugs—adebrelimab, apatinib, and tegafur—in 32 people with advanced esophageal cancer that has not responded to first-line immunotherapy. The goal is to see if this new mix can shrink tumors or slow the disease. Participants will receive the drugs intravenously and orally over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (an immunotherapy drug), apatinib (a targeted therapy), and tegafur (a chemotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced esophageal cancer that has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and there is no guarantee it will work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact